Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

• PFS was notably different between patients with low and medium LAG-3 tumors, indicating potential treatment variability.
• Patients treated with NIVO plus RELA showed differing outcomes based on LAG-3/CD8+ tumor levels, suggesting biomarker utility.
• Stratified analyses revealed insights into the different responses to immunotherapy in advanced melanoma patients, shaping future treatment routes.
• Findings may support the incorporation of LAG-3 as a biomarker for patient stratification in advanced melanoma treatments.